Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy

References

• Alghamdi M. Familial Mediterranean fever, review of the literature. Clin Rheumatol. 2017;36(8):1707–9.
   PubMed Web of Science ®Google Scholar
• Ozdogan H, Ugurlu S. Familial Mediterranean fever. InternetAvailable from Press Med. 2019;481:e61–76. 10.1016/j.lpm.2018.08.014
   PubMed Web of Science ®Google Scholar
• Sari I, Birlik M, Kasifoglu T. Familial Mediterranean fever: an updated review. Eur J Rheumatol. 2014;1(1):21–33.
   PubMedGoogle Scholar
• Özen S. Update on the epidemiology and disease outcome of familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2018;32(2):254–260.
   PubMed Web of Science ®Google Scholar
• La Regina M, Nucera G, Diaco M, et al. Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet. 2003;11(1):50–56. DOI:10.1038/sj.ejhg.5200916
   PubMed Web of Science ®Google Scholar
• Cerrito L, Sicignano LL, Verrecchia E, et al. Epidemiology of FMF Worldwide. In. 2015:81–90 Available from. doi:10.1007/978-3-319-14615-7_5
   Google Scholar
• Bustaffa M, Koné-Paut I, Ozen S, et al. The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: results from a large international FMF cohort. Semin Arthritis Rheum. 2022;52:1–6.
   Web of Science ®Google Scholar
• Portincasa PC. Biologic agents and more for the treatment of familial Mediterranean fever. the old, the new, and the rare. Curr Med Chem. 2015;23(1):60–86.
   Web of Science ®Google Scholar
• Maggio MC, Corsello G. FMF is not always “fever”: from clinical presentation to “treat to target. Ital J Pediatr. 2020;46(1):1–5.
   PubMed Web of Science ®Google Scholar
• Suticen E, Atas N, Guler AA, et al. Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists. Clin Rheumatol. 2021 Jul 1;40(7):2865–2871. InternetAvailable from. DOI:10.1007/s10067-021-05617-7
   PubMed Web of Science ®Google Scholar
• Koşan Z, Yılmaz S, Bilge Yerli E, et al. Evaluation of the burden of care and the quality of life in the parents of Turkish children with familial Mediterranean fever. J Pediatr Nurs. 2019;48(xxxx):e21–6.
   PubMedGoogle Scholar
• El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant familial Mediterranean fever (FMF). Orphanet J Rare Dis. 2019;14(1):1–12.
   PubMed Web of Science ®Google Scholar
• Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013;43(3):387–391. DOI:http://dx.doi.org/10.1016/j.semarthrit.2013.04.011 InternetAvailable from.
   PubMed Web of Science ®Google Scholar
• Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. InternetAvailable from Nat Rev Rheumatol. 2014;103:135–147. http://dx.doi.org/10.1038/nrrheum.2013.174
   PubMed Web of Science ®Google Scholar
• Ozen S, Kone-Paut I, Gül A. Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47(1):115–120.
   PubMed Web of Science ®Google Scholar
• Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29(4 SUPPL. 67):S77–86.
   PubMed Web of Science ®Google Scholar
• Agenzia Italana del Farmaco. Lists of class a and class H medicinal products [Internet]. [cited 2022 Apr 14]. Available from: https://www.aifa.gov.it/en/liste-farmaci-a-h
   Google Scholar
• European Medicine Agency. Kineret - European public assessment report (EPAR) [Internet]. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret
   Google Scholar
• Gazzetta Ufficiale. GU n.177 del 26-7-2021 Kineret. 2011. p. 1–4.
   Google Scholar
• Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. DOI:10.1136/annrheumdis-2015-208690
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Ilaris - European public assessment report (EPAR) [Internet]. 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris
   Google Scholar
• Gazzetta Ufficiale. GU n.122 del 26-5-2022 - Rinegoziazione Ilaris. 2011. p. 1–4.
   Google Scholar
• Sąhin A, Derin ME, Albayrak F, et al. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Adv Rheumatol. 2020;60(1):1–7.
   Google Scholar
• Patient access monitor. Prezzi Farmaci [Internet] [Internet]. [cited 2022 Apr 14]. Available from: http://pamonitor.it/
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices - budget impact analysis. Value Heal. 2007;10(5):336–347. DOI:10.1111/j.1524-4733.2007.00187.x
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis - Principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Heal. 2014;17(1):5–14. DOI:10.1016/j.jval.2013.08.2291
   PubMed Web of Science ®Google Scholar
• AIFA. Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di un medicinale [Internet]. 2020 [cited 2022 Mar 22]. Available from: https://www.aifa.gov.it/documents/20142/1283800/Linee_guida_dossier_domanda_rimborsabilita.pdf.
   Google Scholar
• Istituto Nazionale di Statistica. Previsioni della popolazione Anni 2020-2070 [Internet]. [cited 2022 May 12]. Available from: https://demo.istat.it/previsioni2017/index.php?lingua=ita
   Google Scholar
• National Health Service England. Clinical commissioning policy: anakinra to treat periodic fevers and autoinflammatory diseases (all ages) [Internet]. 2018. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/1713-anakinra-for-periodic-fever.pdf
   Google Scholar
• Swedish Orphan Biovitrum. Familial Mediterranean fever mapping research. Data on file. 2021.
   Google Scholar
• European Medicine Agency. Kineret: ePAR – product information. Last updated 22 December 2021 [Internet]. [cited 2022 May 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret#product-information-section
   Google Scholar
• Medicine Agency E. Ilaris: ePAR - product information. Last updated 15 October 2021 [Internet]. [cited 2022 May 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris#product-information-section
   Google Scholar
• Perna GP, Ravasio R, Ricciardelli A. Analisi di Budget Impact di Ticagrelor nel Trattamento di Prevenzione in Pazienti con Sindrome Coronarica Acuta. Glob Reg Heal Technol Assess Ital North Eur Spanish. 2017;4(1):grhta.5000255.
   Google Scholar
• Aiello A, Ritrovato D, Pitotti C. Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study. Glob Reg Heal Technol Assess Ital North Eur Spanish. 2018;2018:228424031880480. 2018. DOI:10.1177/2284240318804808.
   Google Scholar
• Yucel IK, Seyahi E, Kasapcopur O, et al. Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. Rheumatol Int. 2012;32(7):1955–1962.
   PubMed Web of Science ®Google Scholar
• Aksu K, Dokuyucu O, Ertenli AI, et al. Cost of familial Mediterranean fever (Fmf) disease in Turkey. Value Heal. 2015 Nov 1 18(7):A666. DOI:10.1016/j.jval.2015.09.2427InternetAvailable from
   Web of Science ®Google Scholar